Dr. Anıl Yıldız

• Tumeurs du sein 5 publications
  Source : OpenAlex / PubMed MeSHVoir les publications
• Tumeurs colorectales 2 publications

Expérience

• 2026Acıbadem Sağlık Grubuacibadem.com.tr
• 2024 - 2026Başakşehir Çam ve Sakura Şehir Hastanesi - Tıbbi Onkoloji Yandal Uzmanıacibadem.com.tr
• 2021İstanbul Çatalca İlyas Çokay Devlet Hastanesi - İç Hastalıkları Uzmanıacibadem.com.tr
• 2021 - 2024İstanbul Üniversitesi Onkoloji Enstitüsü - Onkoloji Yandal Asistanlık Öğrencisiacibadem.com.tr
• 2019 - 2021Ardahan Devlet Hastanesi - İç Hastalıkları Uzmanıacibadem.com.tr
• 2015 - 2019Medipol Üniversitesi Tıp Fakültesi Hastanesi - İç Hastalıkları Araştırma Görevlisiacibadem.com.tr
• 2014 - 2015Çatalca İlyas Çokay Devlet Hastanesi - Pratisyen Hekimacibadem.com.tr
• 2013 - 2014Bağcılar Eğitim ve Araştırma Hastanesi - Genel Cerrahi Araştırma Görevlisiacibadem.com.tr

Formation

• 2024İstanbul Üniversitesi İstanbul Tıp Fakültesi, Tıbbi Onkoloji, Üst Uzmanlıkacibadem.com.tr
• 2019İstanbul Medipol Üniversitesi Tıp Fakültesi, İç Hastalıkları, Uzmanlıkacibadem.com.tr
• 2013Yeditepe Üniversitesi Tıp Fakültesi, Üniversiteacibadem.com.tr

• SpécialitéOncologie médicaleacibadem.com.trD’après la source
• ÉtablissementAcıbadem Maslak Hastanesiacibadem.com.trD’après la source
• Sujet de travailTumeurs du seinDéduit de 5 publications · Version du modèle —D’après la source
• Publications29 publicationsOpenAlex, ORCIDD’après la source
• ORCID0000-0002-6402-4445ORCIDD’après la source
• Dernière synchronisation4 novembre 2026 21:19https://www.acibadem.com.tr/doktor/anil-yildiz/acibadem.com.tr

1. Comparison of First-Line Pembrolizumab Monotherapy Versus Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Multicenter Real-World Study from Turkey

   Medicina, 2026

   DOI 10.3390/medicina62112136 Texte intégral en libre accèsSource : OpenAlex

2. Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR

   Journal of Clinical Medicine, 2026

   DOI 10.3390/jcm15062217 PMID 41899145 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

3. Association of Post-Neoadjuvant Chemotherapy MRI and 18F-FDG PET/CT Findings with Tumor Response and Prognosis in Breast Cancer

   Diagnostics, 2026

   DOI 10.3390/diagnostics16050713 PMID 41827989 Texte intégral en libre accèsSource : OpenAlex

4. Comparison of clinicopathological features and prognoses of de-novo metastatic male and female bladder cancer patients.

   Journal of Clinical Oncology, 2026

   DOI 10.1200/jco.2026.44.7_suppl.867 Source : OpenAlex

5. Clinicopathologic Features of NRG1 Fusion‐Positive Non‐Small Cell Lung Cancer

   Genes, Chromosomes and Cancer, 2026

   DOI 10.1002/gcc.70170 PMID 42706502 Texte intégral en libre accèsSource : ORCID

6. Drug-related problems, adherence and quality of life in outpatients receiving endocrine treatment for hormone receptor-positive breast cancer: A prospective study

   Journal of Oncology Pharmacy Practice, 2026

   DOI 10.1177/10781552261494092 PMID 42847533 Texte intégral en libre accèsSource : ORCID

7. Prognostic Value of the Lung Immune Prognostic Index in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: A Real-World Analysis Beyond PD-L1 Expression

   Diagnostics, 2026

   DOI 10.3390/diagnostics16182890 PMID 42793675 Texte intégral en libre accèsSource : ORCID

8. Impact of HER2-low status on survival outcomes in patients with metastatic breast cancer treated with cdk4/6 inhibitors: A single-center experience

   Medical Journal of Western Black Sea, 2026

   DOI 10.29058/mjwbs.1844079 Texte intégral en libre accèsSource : ORCID

9. Prognostic Value of the Lung Immune Prognostic Index in Advanced Non–Small Cell Lung Cancer Receiving Nivolumab: A Real-World Analysis Beyond PD-L1 Expression

   2026

   DOI 10.20944/preprints202605.1554.v1 Texte intégral en libre accèsSource : ORCID

10. Prognostic Impact of ABO/Rh Blood Group–Systemic Inflammation Indices Interactions in Small-Cell Lung Cancer

    Biomedicines, 2026

    DOI 10.3390/biomedicines14051051 PMID 42193377 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID